about
Post-Genomics and Vaccine Improvement for LeishmaniaEnhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigenLive vaccination tactics: possible approaches for controlling visceral leishmaniasisImmunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccineEvaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica.In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy.Arginase activity in pathogenic and non-pathogenic species of Leishmania parasitesPUF Proteins: Cellular Functions and Potential Applications.Leishmania-based expression systems.Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies.Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model.Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity.Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis.Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity.A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation.Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis.Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population.Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening.Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropicaLactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice
P50
Q26752532-27488D56-8C4B-4D4F-A5A5-C85F1093A0B3Q28541600-8C8228A9-948C-48BF-AF70-6F697E1D5B44Q28542081-28B8D5B0-0FC7-4EC6-9495-4D950BD15015Q35326248-273C4269-6476-48BB-9297-6984BC0AEEBBQ35702943-4FAF4E46-2490-4896-AC92-78C2B6CE678DQ35836338-806D865A-D981-447E-99D3-F16C93A18B3FQ36050879-5F3FC790-132B-428A-B6CC-46E3D265FCABQ36768985-6711FC0A-7B1A-4962-9028-D133FFF9503DQ38678821-87934937-F839-4920-B220-E843F4DB45D4Q38820673-655007DF-1595-4554-8529-AD5277671A84Q38902366-289C1C34-8940-4C73-8C80-75A4DB922D39Q39235934-2F940A59-1A83-4F87-BD78-4B9305791441Q39615381-4B7A3400-8F0C-4A16-990F-F3D9D3DCD23BQ40616351-031CDAD4-C88F-4D69-9BF7-E725C334238AQ40663539-D3A917EA-221E-4249-9F8B-83B73930FD48Q40761674-5D86BABA-8D6C-41CA-A70F-1B5F8C0DE9B5Q40864828-271A0525-F6FD-4C59-8B0F-0C8086854225Q41511998-7AC63732-54FE-44C8-8732-B02B9492ACB5Q42182831-2324BE57-B661-4BA3-AE85-608DEE70AF46Q42632604-632D351A-4105-4256-864D-0953B16656BEQ43086688-64078F4C-AB00-4364-9DA0-025B2312B3BBQ43604612-F6A94EED-C8D5-49AB-90C6-95EA44596AAEQ44022754-ECE89918-5B92-41D8-A391-9DBB9A88803CQ44072786-3D264C37-A6C8-481E-AD51-7040019DB0EFQ44525462-1AE8E7DE-6737-423E-9C63-6FC671B8F1E1Q44744837-7FD43BEA-029E-40B1-B7A0-B513C1DE8059Q44824156-2E6BA352-3A96-4F39-9CFA-B7F03F31261CQ45888118-8C7C1687-02E7-46E5-A77D-455F09121949Q46332681-39CCA573-719F-43BB-A079-2BD935E8282BQ46480653-0BDFAB71-60EC-4C89-8944-CE0B19C29E23Q46841223-12A1F393-19C7-4E29-A545-2EE4E22DB7D8Q48059220-F717E0CE-1878-43A2-BF8F-73CFFD0F23FEQ50229835-3C3639E1-BFDC-4D9C-A328-5AE383599C61Q54318553-24768854-72E7-48AB-85EF-86AAA1ED1C62Q91772325-2BB495E1-0CF6-4B0D-B0A8-0982597A9BBEQ92401918-1D3BFA3C-F481-478A-9F09-178187E9B296
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tahereh Taheri
@ast
Tahereh Taheri
@en
Tahereh Taheri
@es
Tahereh Taheri
@nl
Tahereh Taheri
@sl
type
label
Tahereh Taheri
@ast
Tahereh Taheri
@en
Tahereh Taheri
@es
Tahereh Taheri
@nl
Tahereh Taheri
@sl
prefLabel
Tahereh Taheri
@ast
Tahereh Taheri
@en
Tahereh Taheri
@es
Tahereh Taheri
@nl
Tahereh Taheri
@sl
P106
P1153
6507867441
P31
P496
0000-0002-2619-6879